TIRANA, July 13 – Italian biopharmaceutical company Dompé has announced its presence in Albania with an office in Tirana in a strategic choice for its expansion in the Balkan region and Eastern Europe.
The Tirana branch is the second overseas office Dompé has opened after the New York office the Italian pharmaceutical group last year.
“Albania has succeeded in creating suitable conditions for attracting investment and skills, making the health sector one of the strategic assets for the country’s growth,” said Sergio Dompé, the company’s president.
“The goal is to establish ourselves as a responsible partner in the Albanian healthcare sector, building a positive collaboration and a constant dialogue with stakeholders,” he added.
Albania’s Prime Minister Edi Rama described the presence of Dompé in Albania as a major development to improve the quality of health in Albania and make Albania a pharmaceutical hub in the region.
“The opening of a permanent representation office in Tirana is a major development to improve the quality and the image of a health system which strongly needs to increase its reliability,” said Rama.
Italian ambassador to Albania, Massimo Gaiani, said Dompé’s arrival in Albania was good news for Italian companies in Albania and their confidence in investing in Albania, serving the country’s further development.
Eugenio Aringhieri, the CEO of Dompé Group, said the Tirana branch office was a strategic choice in the company’s growth toward the markets of the Balkan region and Eastern Europe. “Albania is an important partner for Italy, especially in a field such as healthcare, in which there is a tangible potential to attract international investment. Dompé fits into this context with the awareness that it is able to actively contribute to the renewal process in progress that aims at the improvement of services and solutions for the well-being of people,” said Aringhieri.
In the initial phase, Dompé will be present with the product range of the Primary Care line, in both the OTC (over the counter) and prescription drugs areas. The company also plans the launch of new medicinal products in its first two years of operations in Albania.
